Grabczyk E, Usdin K
Section on Genomic Structure and Function, Laboratory of Molecular and Cellular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0830, USA.
Nucleic Acids Res. 2000 Dec 15;28(24):4930-7. doi: 10.1093/nar/28.24.4930.
Expanded GAA.TTC trinucleotide repeats in intron 1 of the frataxin gene cause Friedreich's ataxia (FRDA) by reducing frataxin mRNA levels. Insufficient frataxin, a nuclear encoded mitochondrial protein, leads to the progressive neurodegeneration and cardiomyopathy characteristic of FRDA. Previously we demonstrated that long GAA.TTC tracts impede transcription elongation in vitro and provided evidence that the impediment results from an intramolecular purine.purine.pyrimidine DNA triplex formed behind an advancing RNA polymerase. Our model predicts that inhibiting formation of this triplex during transcription will increase successful elongation through GAA.TTC tracts. Here we show that this is the case. Oligodeoxyribonucleotides designed to block particular types of triplex formation provide specific and concentration-dependent increases in full-length transcript. In principle, therapeutic agents that selectively interfere with triplex formation could alleviate the frataxin transcript insufficiency caused by pathogenic FRDA alleles.
弗里德赖希共济失调(FRDA)基因内含子1中扩展的GAA.TTC三核苷酸重复序列通过降低frataxin mRNA水平导致弗里德赖希共济失调。frataxin是一种核编码的线粒体蛋白,其不足会导致FRDA特有的进行性神经退行性变和心肌病。此前我们证明,长的GAA.TTC序列在体外会阻碍转录延伸,并提供证据表明这种阻碍是由前进的RNA聚合酶后面形成的分子内嘌呤-嘌呤-嘧啶DNA三链体导致的。我们的模型预测,在转录过程中抑制这种三链体的形成将增加通过GAA.TTC序列的成功延伸。在此我们表明情况确实如此。设计用于阻断特定类型三链体形成的寡脱氧核糖核苷酸可使全长转录本特异性且浓度依赖性增加。原则上,选择性干扰三链体形成的治疗剂可以缓解由致病性FRDA等位基因引起的frataxin转录本不足。